A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)

Wen Zhong(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Amineh Ghaderi(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Jeanette Lundin(Karolinska University Hospital), Parviz Kokhaei(Arak University of Medical Sciences), Anders Österborg(Karolinska University Hospital), Marzia Palma(Karolinska University Hospital), Tom A. Mulder(Karolinska University Hospital), Johan Schultz(Kancera (Sweden)), H Mellstedt(Karolinska University Hospital), Thomas Olin(Kancera (Sweden))
Cancers
November 13, 2024
10.3390/cancers16223821
Cited by 5

Related Papers

Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
|Blood|1998|306
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
|Journal of Clinical Oncology|1998|258
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202